Holen Sie sich die Stockscreener-App
100.04
2.05%
-2.09
Handel nachbörslich:
102.02
1.98
+1.98%
Schlusskurs vom Vortag:
$102.13
Offen:
$102.01
24-Stunden-Volumen:
669.30K
Relative Volume:
0.52
Marktkapitalisierung:
$8.69B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-42.43
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
+2.78%
1M Leistung:
+13.82%
6M Leistung:
+199.88%
1J Leistung:
+462.34%
1-Tages-Spanne:
$98.87
$105.05
1-Wochen-Bereich:
$97.00
$105.05
52-Wochen-Spanne:
$14.51
$105.09
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
100.04 | 8.87B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
SYRE|Spyre Therapeutics Inc|Price:99.950|Chg%:-2.180 - TradingKey
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Spyre Therapeutics Inc (SYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spyre Therapeutics Market Sentiment - Benzinga España
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Inc (SYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ETFs Investing in Spyre Therapeutics, Inc Stocks - TradingView
Spyre Therapeutics, Inc. earns Great Place to Work certification for 2026 - Traders Union
SYRE Stock Draws Analyst Upgrades As Volatility Spikes - StocksToTrade
Why Spyre Therapeutics (SYRE) Stock Is Up Today - Moomoo
Spyre Therapeutics stock hits 52-week high at 102.46 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 102.46 USD - Investing.com
Spyre Therapeutics (SYRE) Slides 4.1% as Biotech Sector Faces HeadwindsIchimoku Cloud - dars.gov.et
Mizuho raises Spyre stock price target to $120 on IBD data - Investing.com UK
Spyre Therapeutics, Inc. participates in key Boston investor event - Traders Union
Mizuho raises Spyre stock price target to $120 on IBD data By Investing.com - Investing.com South Africa
SYRE Maintained by Mizuho -- Price Target Raised to $120 - GuruFocus
Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating - marketscreener.com
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119 - Moomoo
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - Moomoo
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119 - Moomoo
Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics (SYRE) Study result Summary - Quartr
Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $98 - Moomoo
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE) - Seeking Alpha
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):